Inquiry Basket
Loading ......
DXd has become a central topic in modern drug discovery and targeted therapeutic research, particularly within the field of antibody–drug conjugates (ADCs). For researchers working in medicinal chemistry, payload design, linker engineering, or targeted delivery systems, understanding DXd is essential for navigating current and next-generation conjugate technologies. This resource provides a comprehensive, research-oriented overview of DXd—its origin, chemical characteristics, mechanism of action, and why it has emerged as a preferred payload in advanced targeting strategies.
DXd typically refers to deruxtecan, a highly potent topoisomerase I inhibitor derived from the camptothecin class of compounds. In research literature, DXd is best known as a cytotoxic payload engineered specifically for use in antibody–drug conjugates and other targeted delivery platforms.
Unlike traditional small-molecule cytotoxins, DXd was optimized not only for potency, but also for conjugation compatibility, intracellular stability, and controlled release. These features distinguish DXd from earlier payload generations and explain its widespread adoption in ADC research pipelines.
From a chemical standpoint, DXd is a synthetic camptothecin analog designed to overcome several limitations of first-generation topoisomerase I inhibitors. Key properties include:
These features allow DXd to remain stable during circulation or in vitro incubation while being efficiently released once internalized into target cells—a critical requirement for precision delivery research.
DXd exerts its biological effect through inhibition of DNA topoisomerase I, an enzyme essential for relieving torsional stress during DNA replication and transcription.
Mechanistically, DXd:
From a research perspective, DXd is valued for its cell cycle–dependent activity, predictable DNA damage signature, and reproducible intracellular effects across multiple experimental systems.
Payload selection remains one of the most critical challenges in ADC development. DXd has gained prominence because it addresses several long-standing bottlenecks in conjugate research:
DXd exhibits sub-nanomolar cytotoxicity, allowing researchers to use low drug-to-antibody ratios (DARs) while maintaining strong biological effects.
DXd metabolites can diffuse across cell membranes after release, enabling bystander killing in heterogeneous target environments—an important consideration in complex biological models.
DXd is commonly paired with enzyme-cleavable peptide linkers, such as tetrapeptide-based systems, which are efficiently processed in lysosomal compartments.
In conjugate research, DXd is rarely discussed in isolation. Its performance is closely tied to linker chemistry, making it a useful model payload for studying structure–function relationships in ADC systems.
Researchers often explore:
DXd's chemical flexibility allows systematic investigation of these variables, making it a preferred payload in comparative linker studies.
In laboratory settings, DXd-based conjugates are widely used in:
Because DXd produces a consistent and well-characterized biological response, it serves as a benchmark payload when evaluating new targeting ligands, antibodies, or delivery platforms.
Compared with microtubule inhibitors (such as auristatins or maytansinoids), DXd offers several research advantages:
These attributes make DXd particularly attractive in exploratory research aimed at overcoming resistance mechanisms or improving selectivity.
Despite its advantages, DXd also presents challenges that researchers must carefully manage:
As a result, DXd is often used in iterative optimization workflows, where conjugation chemistry, linker design, and targeting strategy are refined in parallel.
While most commonly associated with ADCs, DXd is increasingly explored in alternative targeted delivery formats, including:
This expanding application landscape highlights DXd's versatility as a research payload rather than a single-use molecule.
Ongoing research involving DXd focuses on:
As targeting technologies become more sophisticated, DXd continues to serve as a reference standard for evaluating new concepts in precision drug delivery.
No. DXd belongs to the topoisomerase I inhibitor class, which has been studied for decades. However, DXd represents a new generation within this class, specifically engineered for conjugation, controlled release, and intracellular activation, distinguishing it from earlier camptothecin-based compounds.
DXd combines high cytotoxic potency, chemical flexibility for linker attachment, and predictable intracellular processing. These characteristics allow researchers to achieve strong biological activity at relatively low drug-to-antibody ratios while maintaining acceptable conjugate stability during in vitro and in vivo studies.
Unlike microtubule inhibitors, DXd targets DNA replication machinery by inhibiting topoisomerase I. This distinct mechanism enables:
DXd is most frequently conjugated using enzyme-cleavable peptide linkers, particularly tetrapeptide-based systems that are efficiently processed in lysosomal environments. These linkers enable selective intracellular release while maintaining plasma or extracellular stability in research models.
References
| Target | Cat. No. | Product Name | Host | Application | |
| DXD | CABT-L828M | Mouse Anti-Dxd monoclonal antibody, clone 13 | Mouse | ELISA | Inquiry |
| CABT-L0103Y | Mouse Anti-DXD&Exatecan monoclonal Antibody, clone N793 | Mouse | PK, PD, IA, ELISA | Inquiry | |
| CABT-L1055X | Anti-DXD monoclonal antibody | Rabbit | ELISA | Inquiry | |
| CABT-L1056X | Anti-DXD monoclonal antibody | Rabbit | ELISA | Inquiry | |
| CABT-L1061X | Anti-DXD monoclonal antibody, Biotin | Rabbit | ELISA | Inquiry | |
| CABT-L1062X | Anti-DXD monoclonal antibody, PE | Rabbit | FC | Inquiry |
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| DXD | DEIA-JY25377 | Deruxtecan (Dxd) ADC ELISA Kit | Quantitative | Serum, plasma | Inquiry |
Loading ......
